Nestin蛋白在白血病及其他恶性血液肿瘤中的研究进展  

Progress on nestin express in leukemia and other hematological malignant tumor

作　　者：王艳飞[1,2] 梅芬[1] 撒亚莲[2] 

机构地区：[1]昆明理工大学医学院,昆明650500 [2]云南省第一人民医院临床基础医学研究所,昆明650032

出　　处：《生命科学》2016年第7期793-798,共6页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(31460298;81460073);云南省科技厅-昆明医科大学联合专项应用基础研究项目(2014FZ070;2014FB092)

摘　　要：Nestin蛋白为第Ⅵ类中间丝蛋白,最初被认为是神经干细胞标志物,表达于神经干/祖细胞、部分成体组织中的前体细胞及细胞修复阶段,还在多种肿瘤细胞中表达,并和P53、Wnt/β-catenin、AktGSK3β-Rb等肿瘤细胞增殖调控信号通路相关。Nestin蛋白在白血病及其他恶性血液肿瘤中异常表达,并且参与急性淋巴白血病(acute lymphoma leukemia,ALL)细胞抗药性niche的形成,以及急性髓系白血病细胞对骨髓微环境的损伤。目前,临床阶段已在白血病和多发性骨髓瘤患者中检测到nestin蛋白表达,其可以作为区分髓系和淋巴系白血病的标志物。在ALL中,敲除nestin可破坏白血病抗药性niche,这可能作为一种治疗ALL的新方法。Nestin is a class VI intermediate filament （IF） protein originally described as a neural stem cell marker. It was expressed in neural stern cells, adult progenitor cells and repaired period of cell damage as well as some types of tumor cells, which is related to P53, Wnt/β-catenin, Akt-GSK3β-Rb and other tumor proliferation signal pathway. It was reported that the expression of nestin has also been detected in leukemia and other hematological malignant tumor. Nestin is involved in the formation of drug resistance niche in acute lymphoblastic leukemia （ALL）, and takes part in the bone marrow （BM） microenvironments damage linked to acute myeloid leukemia cell. It has been found that nestin expressed in leukemia and multiple myeloma patients. It might become a useful biomarker for identification of AML and ALL. More importantly, the knockdown of nestin can break the protective resistance niche in response to chemotherapy, and it might be a new target for ALL leukemia patients.

关 键 词：巢蛋白 白血病 多发性骨髓瘤 

分 类 号：R730.51[医药卫生—肿瘤]